Please assess the completion status of the following clinical trial:

Trial Title: Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with a previously untreated, T1 or T2, N0-N2b transorally resectable (as determined by the treating surgeon), histologically proven HPV positive, squamous cell carcinoma (SCC) of the oropharynx.~2. Eastern Cooperative Oncology Group (ECOG) PS 0-2.~3. Age \>/= 18 years.~4. Negative serum pregnancy test in females of childbearing potential.~5. Patients must sign a study-specific informed consent form prior to treatment.~Exclusion Criteria:~1. Evidence of distant metastases (below the clavicle) by clinical or radiographic examination.~2. Evidence of any other primary cancers or metastases. Evidence of deep soft-tissue or bony invasion, which would preclude TMIS by clinical and/or radiographic exam.~3. Contraindications to general anesthesia.~4. Patients who have had chemotherapy or radiotherapy to the oropharynx prior to entering the study.~5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~6. Patients with tumors whose resection would necessitate a free-tissue transfer for reconstruction of the surgical defect.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transoral Robotic Surgery (TORS) (Type: EXPERIMENTAL): Transoral robotic surgery performed utilizing Intuitive Surgical da Vinci Surgical System. Utilizing robotic surgical system, tumor excised with wide surgical margins of 0.5-1 cm. Functional assessment performed at pre-treatment, within 1-4 weeks post-op from TORS (before adjuvant therapy), and after completion of treatment at the following time points: 6 months (±2 months), 12 months (±2 months), and 24 months (±6 months). Functional measures include video-fluoroscopic examination of swallowing (modified barium swallow \[MBS\] study) with administration of the Performance Status Scale-Head and Neck (PSS-HN) and MD Anderson Dysphagia Inventory (MDADI) questionnaire.

Based on this trial design, predict the completion outcome and termination type (if applicable).